葡萄糖代谢紊乱：诊断与治疗的挑战与机遇
Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment.
作者信息
Vekic Jelena, Silva-Nunes José, Rizzo Manfredi
机构信息
Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de Lisboa Central, 1069-166 Lisbon, Portugal.
出版信息
Metabolites. 2022 Jul 29;12(8):712. doi: 10.3390/metabo12080712.
Abstract
Alterations of glucose metabolism are recognized as one of the most important risk factors for the development and complications of cardiometabolic diseases [...].
摘要
葡萄糖代谢改变被认为是心脏代谢疾病发生和并发症的最重要危险因素之一[...]。
相似文献
1
Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment.
Metabolites. 2022 Jul 29;12(8):712. doi: 10.3390/metabo12080712.
2
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.
Metabolites. 2021 Sep 9;11(9):611. doi: 10.3390/metabo11090611.
3
In women with PCOS, waist circumference is a better surrogate of glucose and lipid metabolism than disease status per se.
Clin Endocrinol (Oxf). 2018 Apr;88(4):565-574. doi: 10.1111/cen.13542. Epub 2018 Feb 7.
4
Sex differences in cardiometabolic disorders.
Nat Med. 2019 Nov;25(11):1657-1666. doi: 10.1038/s41591-019-0643-8. Epub 2019 Nov 7.
5
Thyrotropin Levels Are Associated with Cardiometabolic Risk Factors in Euthyroid Adolescents.
Thyroid. 2016 Oct;26(10):1441-1449. doi: 10.1089/thy.2016.0055. Epub 2016 Sep 27.
6
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
J Hypertens. 2007 Jan;25(1):177-86. doi: 10.1097/HJH.0b013e3280108e6f.
7
Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges.
Curr Drug Targets. 2017;18(15):1754-1778. doi: 10.2174/1389450116666150804110412.
8
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases.
Front Pharmacol. 2020 Aug 26;11:1247. doi: 10.3389/fphar.2020.01247. eCollection 2020.
9
Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline-Does Insulin Have Anything to Do with It? A Narrative Review.
J Clin Med. 2021 Apr 6;10(7):1532. doi: 10.3390/jcm10071532.
10
Fructose vs. glucose and metabolism: do the metabolic differences matter?
Curr Opin Lipidol. 2014 Feb;25(1):8-19. doi: 10.1097/MOL.0000000000000042.
引用本文的文献
1
The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic factors and anthropometric indices in women with prediabetes: a study protocol for a double-blind randomized controlled trial.
BMC Complement Med Ther. 2025 Aug 6;25(1):299. doi: 10.1186/s12906-025-05034-2.
2
Machine learning and deep learning in diabetology: revolutionizing diabetes care.
Front Clin Diabetes Healthc. 2025 May 27;6:1547689. doi: 10.3389/fcdhc.2025.1547689. eCollection 2025.
3
The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers' Glucose Metabolism: A Systematic Review and Meta-Analysis.
Nutrients. 2025 May 15;17(10):1689. doi: 10.3390/nu17101689.
4
Diabetes and gut microbiome.
Front Microbiol. 2025 Jan 7;15:1451054. doi: 10.3389/fmicb.2024.1451054. eCollection 2024.
5
Rare Sugar Metabolism and Impact on Insulin Sensitivity along the Gut-Liver-Muscle Axis In Vitro.
Nutrients. 2023 Mar 25;15(7):1593. doi: 10.3390/nu15071593.
6
Association of cyclophilins and cardiovascular risk factors in coronary artery disease.
Front Physiol. 2023 Mar 1;14:1127468. doi: 10.3389/fphys.2023.1127468. eCollection 2023.
7
Does the Hyperglycemia Impact on COVID-19 Outcomes Depend upon the Presence of Diabetes?-An Observational Study.
Metabolites. 2022 Nov 15;12(11):1116. doi: 10.3390/metabo12111116.
本文引用的文献
1
Maternal Glycemic Spectrum and Adverse Pregnancy and Perinatal Outcomes in a Multiracial US Cohort.
J Cardiovasc Dev Dis. 2022 Jun 4;9(6):179. doi: 10.3390/jcdd9060179.
2
Uptake of guideline-recommended postpartum diabetes screening among diverse women with gestational diabetes: associations with patient factors in an integrated health system in USA.
BMJ Open Diabetes Res Care. 2022 Jun;10(3). doi: 10.1136/bmjdrc-2021-002726.
3
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.
Front Immunol. 2022 May 27;13:890517. doi: 10.3389/fimmu.2022.890517. eCollection 2022.
4
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.
Diabetes Metab Syndr Obes. 2022 Apr 5;15:1023-1030. doi: 10.2147/DMSO.S351982. eCollection 2022.
5
Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus.
Curr Diab Rep. 2022 Mar;22(3):95-115. doi: 10.1007/s11892-022-01453-4. Epub 2022 Mar 10.
6
Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.
Medicina (Kaunas). 2022 Feb 16;58(2):299. doi: 10.3390/medicina58020299.
7
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.
Metabolites. 2022 Jan 24;12(2):108. doi: 10.3390/metabo12020108.
8
Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence.
Endocr Pract. 2022 Apr;28(4):425-432. doi: 10.1016/j.eprac.2022.02.003. Epub 2022 Feb 11.
9
Spectrum of Phenotypes and Causes of Type 2 Diabetes in Children.
Annu Rev Med. 2022 Jan 27;73:501-515. doi: 10.1146/annurev-med-042120-012033.
10
New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
Diabetes Ther. 2021 Jun;12(6):1605-1611. doi: 10.1007/s13300-021-01065-3. Epub 2021 May 4.
Zotero 插件